e-learning
resources
Amsterdam 2011
Tuesday, 27.09.2011
Treatment of tuberculosis and adverse drug reactions
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Allergic reactions to rifampicin in tuberculosis treatment
F. Chermiti Ben Abdallah, I. Zayani, A. Chtourou, S. Taktak, R. Mahouachi, A. Ben Kheder (Ariana, Tunisia)
Source:
Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Session:
Treatment of tuberculosis and adverse drug reactions
Session type:
Thematic Poster Session
Number:
4410
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Chermiti Ben Abdallah, I. Zayani, A. Chtourou, S. Taktak, R. Mahouachi, A. Ben Kheder (Ariana, Tunisia). Allergic reactions to rifampicin in tuberculosis treatment. Eur Respir J 2011; 38: Suppl. 55, 4410
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Tolerance of cycloserine in combined therapy of tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 315s
Year: 2001
Treatment results of cases of severe pulmonary tuberculosis with using rifabutin
Source: Eur Respir J 2001; 18: Suppl. 33, 339s
Year: 2001
Manifestations of hypersensitivity to anti-tuberculosis drugs
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018
High-dose rifampicin and rifapentine in tuberculosis treatment
Source: International Congress 2015 – Tuberculosis: short-course chemotherapy
Year: 2015
Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy
Source: Eur Respir J 2005; 25: 324-328
Year: 2005
Antituberculosis fixed multi-dose combination and single drug therapy in active tuberculosis: What is about drug hypersensitivity reactions?
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016
Place of azoles in the treatment of allergic bronchopulmonary candidiasis
Source: Eur Respir J 2006; 28: Suppl. 50, 52s
Year: 2006
Adverse reactions in the treatment of patients with non-tuberculous pulmonary mycobacteriosis.
Source: Virtual Congress 2021 – Advances in diagnosis, treatment and clinical management of nontuberculous mycobacterial disease
Year: 2021
Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III
Year: 2013
Desensitization therapy for allergic reactions of antituberculous drugs
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis
Source: Eur Respir J 2003; 22: Suppl. 45, 524s
Year: 2003
Adverse reaction of TB treatment with 2nd line drugs in a tuberculosis TB dispensary
Source: Eur Respir J 2004; 24: Suppl. 48, 648s
Year: 2004
Evaluation of co-trimoxazole in the treatment of multidrug-resistant tuberculosis
Source: Eur Respir J 2013; 42: 504-512
Year: 2013
Tuberculosis 1995–2004: evaluation of the resistance of mycobacterium tuberculosis to anti-TBC drugs in Greece
Source: Eur Respir J 2006; 28: Suppl. 50, 589s
Year: 2006
Adverse effects of moxifloxacin during tuberculosis treatment
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
High-dose rifampicin in tuberculosis: experiences from a Dutch tuberculosis centre
Source: International Congress 2019 – Drug-resistant tuberculosis
Year: 2019
Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction
Source: Eur Respir Rev 2009; 18: 295-299
Year: 2009
The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease
Source: Eur Respir J 2015; 45: 1177-1179
Year: 2015
Adverse reactions to the tuberculosis treatment
Source: Eur Respir J 2001; 18: Suppl. 33, 340s
Year: 2001
Newer fluoroquinolones for treating respiratory infection: do they mask tuberculosis?
Source: Eur Respir J 2010; 35: 606-613
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept